Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 3

Conditions

Multiple Myeloma 38Lymphoma, Non-Hodgkin 14Hodgkin Disease 13Leukemia, Lymphocytic, Chronic, B-Cell 12Leukemia 12Myelodysplastic Syndromes 11Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neoplasms, Plasma Cell 10Leukemia, Myeloid, Acute 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Hematologic Neoplasms 6Primary Myelofibrosis 4Recurrence 3Myeloproliferative Disorders 3Lymphoma, Follicular 3Leukemia, Plasma Cell 3Leukemia, Myelomonocytic, Chronic 3Graft vs Host Disease 3Anemia, Aplastic 3Polycythemia Vera 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Hematologic Diseases 2Wilms Tumor 1Thrombocytopenia 1Thrombocythemia, Essential 1Testicular Neoplasms 1Smoldering Multiple Myeloma 1

Interventions

Dexamethasone 10fludarabine phosphate 9Melphalan 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Lenalidomide 7Cyclophosphamide 7Mycophenolic Acid 6Bortezomib 6Tacrolimus 5Calcium Dobesilate 4filanesib 3dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3carfilzomib 3auricularum 3Stem Cell Transplantation 3Sirolimus 3Filgrastim 3liposomal doxorubicin 2ixazomib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Plasma Cell × Stem Cell Transplantation × Plasma cell × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT02504359 2020-11-23

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

OHSU Knight Cancer Institute

Phase 1 Completed
11 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00615589 2016-04-04

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

University of Michigan Rogel Cancer Center

Phase 2 Terminated
22 enrolled 9 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡